Resminostat

Drug Profile

Resminostat

Alternative Names: 4SC-201; BYK 408740; RAS 2410; YHI-1001

Latest Information Update: 31 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nycomed
  • Developer 4SC; Yakult Honsha
  • Class Antineoplastics; Dimethylamines; Hydroxylamines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma; Hodgkin's disease
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Biliary cancer; Hepatocellular carcinoma; Hodgkin's disease; Mycosis fungoides; Non-small cell lung cancer; Pancreatic cancer; Sezary syndrome
  • Phase I/II Colorectal cancer
  • Phase I Cutaneous T cell lymphoma; Solid tumours
  • Preclinical Diffuse large B cell lymphoma

Most Recent Events

  • 16 May 2017 4SC terminates its licence for resminostat in China, South Korea, Australia, Thailand, Philippines, Indonesia, and Vietnam
  • 16 May 2017 4SC plans to file an marketing authorisation application (MAA) with the EMA in Europe for Cutaneous T‑cell lymphoma
  • 16 May 2017 Yakult Honsha completed enrolment in its phase I/II trial for Hepatocellular carcinoma in Japan and South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top